Medlab Clinical Limited
(ASX:MDC) has been granted approval for two different cannabis based human trials. It was granted approval by the Human Research Ethics Committee.
The medical research and development company says the patent pending medicines, NanaBis and NanaBidial, have two different applications and will be clinically tested at different locations.
The company NanaBis trial will be conducted at the Royal North Shore Hospital’s Northern Cancer Centre on advanced stage cancer patients with intractable pain.
Medlab says the trials mark a significant breakthrough for Australian medicine and are a massive advancement in global cannabis research
Both trials are expected to commence shortly.
Shares in Medlab Clinical Limited
(ASX:MDC) are trading 0.63 per cent higher to 80 cents.
